ERα prevents tumorigenesis of both liver and breast cancer cells through CCN5

Area of Science:

• Molecular Biology
• Cancer Research
• Endocrinology

Background:

• Estrogen receptor alpha (ERα)-mediated signaling is known to prevent hepatic tumorigenesis in mice.
• ERα silencing is implicated in the malignant transformation of ERα-positive breast cancer cells into triple-negative breast cancer.
• The precise mechanisms of ERα-mediated prevention of hepatic and mammary tumorigenesis in humans remain largely unknown.

Purpose of the Study:

• To investigate the functional genomics of ERα targeting in human liver and breast cancer cells.
• To elucidate the mechanisms underlying ERα's role in preventing hepatic and mammary tumorigenesis.
• To identify downstream targets of ERα involved in tumor suppression.

Main Methods:

• Functional genomics study comparing human liver and breast cancer cells.
• In vitro and in vivo genetic assays involving loss or gain of function for ERα.
• Analysis of ERα-mediated regulation of downstream targets.

Main Results:

• Identified cellular communication network factor 5 (CCN5) as a direct downstream target of ERα.
• Demonstrated that ERα suppresses growth and prevents tumorigenesis in both liver and breast cancer cells via CCN5.
• Established the ERα-CCN5 regulatory axis as a suppressor of both hepatic and mammary tumors.

Conclusions:

• The ERα-CCN5 regulatory axis represents a common mechanism for preventing liver and breast cancer in humans.
• ERα acts as a tumor suppressor in both hepatic and mammary contexts through its regulation of CCN5.
• Understanding this pathway offers potential therapeutic strategies for both liver and breast cancers.